Galectin Therapeutics

1 follower


Galectin Therapeutics (NASDAQ: GALT) is applying its leadership in galectin science and drug development to create new therapies for fibrotic disease and cancer. Drug candidates based on the Company’s unique carbohydrate technology target galectin proteins which are key mediators of biologic and pat... Read more

Industries

Employees

11-50

Links

Org chart

Joel Lewis
CEO & President

Joel Lewis

Collapse
Susan Thornton
VP, Regulatory Affairs
Ezra R. Lowe
VP, Clinical & Preclinical Pharmacology
Jeff Katstra
Head of CMC & Pharmaceutical Development
Sharisse Brutto
Director, Project Management
Seth Zuckerman
Senior Director, Biostatistics
Marla Mills-Wilson
Executive Director, Clinical Operations